A compound of formula (I) for use in a method for treatment of pulmonary fibrosis in a human including administering, with a dry powder inhaler, once-a-day to the narrowest parts of the lung tissue of the human an amount of the compound of formula (I) effective to treat the pulmonary fibrosis.

The present invention relates to a group of cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof. The cannabinoid derivatives of the invention are analogues of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the cannabinoid derivatives of the invention

The present invention relates to a group of cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof. The cannabinoid derivatives of the invention are analogues of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the cannabinoid derivatives of the invention

The present invention relates to a compound of formula (I) for use in a method for treatment of pulmonary fibrosis in a human including administering once-a-day to the narrowest parts of the lung tissue of the human an amount of the compound of formula (I) effective to treat said pulmonary fibrosis.

The present invention relates to a compound of formula (I) for use in a method for treatment of pulmonary fibrosis in a human including administering once-a-day to the narrowest parts of the lung tissue of the human an amount of the compound of formula (I) effective to treat said pulmonary fibrosis.

The present invention relates to a water resistant wound cover with high comfort and good air permeability. In particular, the present invention relates to an aqueous wound healing formulation comprising a water-soluble or a water-dispersible polymeric material that does not sting when applied to a minor injury to the skin.

The present invention relates to a water resistant wound cover with high comfort and good air permeability. In particular, the present invention relates to an aqueous wound healing formulation comprising a water-soluble or a water-dispersible polymeric material that does not sting when applied to a minor injury to the skin.

The present invention relates to novel treatments for treating cardiac disease involving fibro-fatty replacement, such as arrhythmogenic cardiomyopathy, atrial fibrillation, myocardial infarction and dilated cardiomyopathy. Such cardiac diseases can e.g. be caused by a mutation in a desmosomal protein such as plakophilin-2 (PKP2). The invention provides for agents for use in the prevention or treatment of such cardiac diseases, wherein the agent is at least one of: a) an agent that causes a reduction in expression in at least one TFAP2 subtype; and, b) an agent that causes a reduction in TFAP2-induced transcription. More preferably the agent is at least one of: a) an inhibitor of TFAP2; and, b) an agent that causes an increase in expression of PKP2.

The present invention relates to novel treatments for treating cardiac disease involving fibro-fatty replacement, such as arrhythmogenic cardiomyopathy, atrial fibrillation, myocardial infarction and dilated cardiomyopathy. Such cardiac diseases can e.g. be caused by a mutation in a desmosomal protein such as plakophilin-2 (PKP2). The invention provides for agents for use in the prevention or treatment of such cardiac diseases, wherein the agent is at least one of: a) an agent that causes a reduction in expression in at least one TFAP2 subtype; and, b) an agent that causes a reduction in TFAP2-induced transcription. More preferably the agent is at least one of: a) an inhibitor of TFAP2; and, b) an agent that causes an increase in expression of PKP2.

An object of the present invention is to provide a measure for treating or preventing a disease or condition that involves AMPK dysregulation, particularly a cancer. The present invention provides a combination therapy using a compound presented by formula (I), a pharmaceutically acceptable salt or a solvate thereof with an immune checkpoint inhibitor.